The document discusses the use of plasma biomarkers for medical purposes such as diagnosis, prognosis, prediction, therapy response monitoring, and drug safety. It notes advantages of using liquid biopsies which involve sampling blood plasma or serum, including that they are minimally invasive, allow for serial sampling, and are more comfortable for patients. The document describes candidate nucleic acid biomarkers that can be measured in plasma, including extracellular cell-free circulating nucleic acids such as messenger RNA, microRNA, long non-coding RNA, and DNA. It indicates that Biogazelle can quantitatively measure over 500 miRNAs, 5000-10,000 mRNAs, and other biomarkers in plasma samples.

1. applications of
plasma biomarkers
diagnosis prognosis
prediction
patient
stratification
!
therapy response
monitoring
drug safety
advantages of
liquid biopsies
serial
sampling
minimally
invasive
reduced
risk
easy patient
comfort
faster
sampling
candidate nucleic acid
biomarkers in plasma
extracellular
cell-free
circulating
nucleic
acid
messenger
RNA
micro-
RNA
long non-
coding RNA
DNA
measuring nucleic acid
biomarkers in plasma at Biogazelle
totest known biomarkers
with quantitative ordigitalPCR **
> 500
miRNAs
5000-10,000
mRNAs
types of
measurement
expression level
sequence variants
(e.g. mutations
and fusion genes)
A A T C G A
A T T C G A
copy number variants
1-100
miRNAs
1-100
mRNAs & lncRNAs
1-10
DNAvariants
© Biogazelle. 2017
reported numbers are the numberofmiRNAs and mRNAs typicallydetected in plasma
reported numbers are the numberoffeatures typicallymeasured in a test
*
**
info@biogazelle.comwww.biogazelle.com
to discovernewbiomarkers
with RNAsequencing *
Customized measurements
of the RNA and DNA biomarkers
in your liquid biopsies
Customized measurements
of the RNA and DNA biomarkers
in your liquid biopsies